Compare AbCellera Biologics Inc (ABCL) vs Vanguard Ultra Short Bond ETF (VUSB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Vanguard Ultra Short Bond ETF — how do they compare? AbCellera Biologics Inc trades at $7.15 (market cap $2.35B), while Vanguard Ultra Short Bond ETF trades at $49.63. The key difference: AbCellera Biologics Inc is trading nearer its 52-week high, Vanguard Ultra Short Bond ETF nearer its low. Which is the better fit depends on your goals.
| ABCL | VUSB | |
|---|---|---|
Market Cap | $2.35B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $8.12 | $50.03 |
52-Week Low | $2.78 | $49.60 |
Enterprise Value | $1.99B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
VUSB trades at $49.66, up 0.04% with a bearish technical signal from moving averages. The ETF offers a yield around 4.35% and recent dividends of $0.17-$0.18, positioning it as a cash alternative amid potential Fed rate changes. Financial ratios are unavailable, but sentiment highlights its role in short-term bond strategies.
Outlook hinges on interest rate trends, with opportunities in yield advantage over money markets. Risks include credit and duration exposure. Analyst coverage is limited for this ETF, requiring investor due diligence on underlying holdings and macroeconomic shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Vanguard Ultra Short Bond ETF
VUSB is an actively managed ETF from Vanguard that invests in a diversified portfolio of high-quality, investment-grade fixed income securities with maturities typically under two years. It is designed to offer higher yield potential than traditional money market funds while maintaining limited price volatility, making it a strategic tool for managing short-term reserves with a 6-to-18-month horizon.
Read more on VUSB →
